Biogen Idec Ma Inc.

Praecis Pharmaceuticals, Inc.

Gang Yao

Russell Colyn Petter

Gnanasambandam Kumaravel

Hairuo Peng

Jeffrey Vessels

Hongfeng Deng

James E Dowling

Ghotas Evindar

Hongfang Yang

Hexi Chang

Sylvie Bernier

Aaron Coffin

The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the Aadenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I). 

[object Object]

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.

Sphingosine-1-phosphate (SIP) receptor agonists

The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy) 

Triazolopyrazines and methods of making and using the same

Growing community of inventors

Sudbury, MA, United States of America

Gang Yao